Loading clinical trials...

AMX0035 in Adult Patients With Wolfram Syndrome | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingPhase 2NCT05676034

AMX0035 in Adult Patients With Wolfram Syndrome

This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.

Lead sponsor: Amylyx Pharmaceuticals Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Amylyx Pharmaceuticals Inc.

Related studies

Monogenic Diabetes Misdiagnosed as Type 1

NCT03988764 · Diabetes Mellitus, Type 1, Monogenic Diabetes, and more

Not Yet Recruiting

Does Recessive Optic Atrophy Due to WFS1 Exist?

NCT07336966 · Wolfram Syndrome 1, Optic Atrophies, Hereditary

Not Yet Recruiting

Mechanisms of Fecal Incontinence in Wolfram Syndrome

NCT07313085 · Wolfram Syndrome, Fecal Incontinence

Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

NCT05659368 · Wolfram Syndrome

Tracking Neurodegeneration in Early Wolfram Syndrome

NCT02455414 · Type 1 Diabetes, Diabetes Insipidus, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 14, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE2

Enrollment12

Start dateMar 2023

Last updatedApr 14, 2026

Condition

Wolfram Syndrome

Locations shown

Washington University

St Louis, Missouri

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions